WEEKLY NEWSLETTER
Oxaliplatin
Examples
| Generic Name | Brand Name |
|---|---|
| oxaliplatin | Eloxatin |
How It Works
Oxaliplatin interrupts cancer cell growth and slows the spread of cancer cells in the body. Oxaliplatin is available for use by intravenous (IV) injection.
Why It Is Used
Oxaliplatin is used in combination with fluorouracil (5-FU) and leucovorin for treatment of advanced colorectal cancer. Oxaliplatin is also used to treat advanced ovarian cancer.
In clinical trials, the combination of oxaliplatin, fluorouracil, and leucovorin, known as FOLFOX, shows promising results as treatment after surgery for stage II and stage III colorectal cancer.1
How Well It Works
Studies show that oxaliplatin may be effective in stopping some cancer cell activity that is resistant to some other anticancer drugs, such as cisplatin and carboplatin. It is most effective when it is used in combination with 5-FU and leucovorin. Test results show that this combination can be effective in slowing growth of the cancer.2
Side Effects
Oxaliplatin can cause serious side effects, including:
- An allergic reaction.
- Numbness, burning, and tingling.
- Loss of feeling.
- Mild, moderate, or severe pain.
- Decreased bone marrow function.
- Sores in the mouth or throat.
- Severe vomiting or diarrhea.
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
What To Think About
Early results from recent studies suggest that the combination of oxaliplatin, 5-FU, and leucovorin may be effective in slowing cancer cell activity in advanced colorectal cancer that has spread to other parts of the body.2
Complete the
new medication information form (PDF)
(What is a PDF document?)
to help you understand this medication.
References
Citations
National Cancer Institute (2005). Oxaliplatin-based regimen prolongs survival after colorectal cancer surgery. Available online: http://www.cancer.gov/clinicaltrials/results/mosiac-trail0603/.
Oxaliplatin (Eloxatin) for advanced colon cancer (2003). Medical Letter on Drugs and Therapeutics, 45(1148): 7–8.
Credits
| Author | Bets Davis, MFA |
| Editor | Susan Van Houten, RN, BSN, MBA |
| Associate Editor | Pat Truman, MATC |
| Primary Medical Reviewer | Anne C. Poinier, MD - Internal Medicine |
| Specialist Medical Reviewer | Arvydas D. Vanagunas, MD - Gastroenterology |
| Last Updated | December 1, 2006 |
Last Updated:
December 1, 2006- Author:
- Bets Davis, MFA
- Medical Review:
- Anne C. Poinier, MD - Internal Medicine
Arvydas D. Vanagunas, MD - Gastroenterology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.




